BioTrinity April 2016 soloMER Biologics: Next-generation therapeutics for the treatment of auto-inflammatory disease Dr Caroline Barelle CEO

soloMERs – small, simpler, stable and more effective than antibodies Elasmogen – proprietary soloMER technology soloMERs – small, simpler, stable and more effective than antibodies Pipeline Initial products for treatment of auto-inflammatory eye disease Expansion of opportunity into other anti-inflammatory conditions (IBD) Focus on Orphan indication Uveitis with £ 3.5 B market opportunity Comprehensive IP portfolio & FTO position Patents - immunisation, libraries, humanization, re-formatting, products Experienced Management and Science Team Track record of successful delivery to the clinic and commercial exits £2 M non-dilutive and £850 K dilutive cash raised Looking to raise £5 M Series A funding +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

soloMERs are different VNARs are the smallest naturally occurring, binding domains soloMERs are fully humanized, clinical candidate VNAR domains Four loops in a single domain of approx 11 kDa Extended loops up to 35 amino acid residues Predisposed to bind cryptic epitopes Pockets, grooves - eg enzymes and receptors Novel and “druggable” small proteins Small, stable, soluble and flexible formatting Comprehensive IP advantage Non-antibody domain avoiding complex antibody landscape soloMERs bind cryptic epitopes +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Anti-inflammatory therapeutics market Predicted to grow to over $90 billion by 2017 (CAGR 6% global, 9% in Asia) Use of Corticosteroids limits sustained market growth Severe side effects and 30% non-responders Anti-inflammatory biologics make up 55% of market in 2014 Respiratory, arthritis, MS portfolios are 80% of drugs in development Orphan disease such as Uveitis have only a few drugs in the clinic Repositioning of existing drugs rather than bespoke or tailored therapies Elasmogen is delivering market need by tailoring anti-inflammatory therapy through site-specific drug delivery +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Our pathway to ocular products soloMER Generation (high affinity, specificity and functionality) PoC in vivo ELN/21 demonstrates equivalent anti-inflammatory protection in a CIA mouse model Anti-inflammatory Site Specific Delivery soloMERTM USPs (small, stable, soluble) Targeting Inflammatory Ocular Disease +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Primary indication - Uveitis Unmet Clinical need 70% auto-immune disease (target population) Current mainstay therapy are systemic corticosteroids 1/3 patients are unresponsive (target population) Market Opportunity Our target market 120,000 unresponsive patients globally Orphan indication Our projected global market is approximately £3 Bn (treatment cost of £25 k/patient/episode) Characterised by a very rapid (few days) and debilitating inflammation of the uvea +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Efficacy of ELN/21 in a model of Uveitis ELN/21 delivered systemically, demonstrates clinical efficacy in a murine model of IRBP-induced Uveitis A: Untreated (severe) B: Cyclosporin (mild) C : ELN/21 (mild) +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Potency equal to Humira at only 9% of size Site-specific delivery of soloMERs In vitro PoC In vivo delivery Potency equal to Humira at only 9% of size +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Elasmogen’s pipeline +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

The Management Team Chris Jones, Chairman; brings 25 years leadership roles in VC and Fortune 500 companies and is currently Chairman of Mologic. Chris has raised over $40 M in funding was CEO of GlySure and CEO of Tensys Medical taking the company to trade sale. Caroline Barelle, CEO; has a strong commercial, bio-partnering and biologics drug discovery/development background having led Teams at Wyeth and subsequently Pfizer in Global Bio- therapeutic Technologies. Prior to this she was Alliance and Programs Manager at Haptogen Ltd. Tim Morley, Pre-clinical/Regulatory; has over 25 years’ experience in drug discovery, regulatory safety and development with both major Pharmaceutical and start-up companies. Currently he is senior director of Pre-Clinical Drug Discovery at Smith and Nephew. . Andy Porter, CTO; was the founder of Haptogen Ltd, acquired in 2007, by Wyeth Inc. and has been on the Board of NovaBiotics Ltd since 2009. NovaBiotics currently has two products in Ph 2 clinical trials, a global licensing deal with Taro Inc and a City funding round by Woodford Investment Management. +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Candidate molecules in two inflammatory indications Seeking Series A : £5 M £5.0 M will deliver: Candidate molecules in two inflammatory indications ELN/21 - IND ready in auto-inflammatory eye disease ELN/22 - pre-clinical PoC completed An established world-class operational capability Discovery and late stage pre-clinical development of soloMERs Recruit a Clinical Development Director Multiple platform deals capable of generating future revenue streams License NDure and progress towards “first-in-man” studies +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com

Validated orphan drug target with a market worth £3 B Take Home Validated orphan drug target with a market worth £3 B Broader market opportunities in auto-inflammatory disease achievable Experienced management team and SAB Strong IP & FTO position (Platform, Products) Commercial Partners in place, milestones achieved Multiple licensing and collaboration opportunities +44 1224 438545 • caroline.barelle@elasmogen.com • www.elasmogen.com